Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Phase I Clinical Trial to Identify Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Anti-cancer Efficacy of NOV140101(IDX1197HCl) in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

Open-label, Phase I Clinical Trial to Identify Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Anti-cancer Efficacy of NOV140101(IDX1197HCl) in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venadaparib (Primary)
  • Indications Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Prostate cancer; Solid tumours; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors Idience

    • Most Recent Events

    • 18 Nov 2021 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2021 Results (Data cut off date- 8 Feb 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 13 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top